Abstract:Background: Anorexia Nervosa (AN) is a serious mental illness characterized by emaciation, an intense fear of gaining weight despite being underweight, and distorted body image. Few treatments reverse the core symptoms in AN such as profound aversion to food and food avoidance. Consequently, AN has a chronic and relapsing course and the highest mortality rate of any psychiatric illness. A more complete understanding of the disease pathogenesis is needed in order to develop better treatments and improve AN outcome. The pathogenesis and psychopathophysiology of AN can be better elucidated by combining longitudinal phenotyping with multiple "omics" techniques, including genomics, proteomics, lipidomics, and metabolomics. Design: This paper summarizes the key findings of a series of interrelated studies including new experimental data and previously published data, and describes our current initiatives and future directions. Results: Exon sequencing data was analyzed in 1205 AN and 1948 controls. Targeted metabolomics, lipidomics, and proteomics data were collected in two independent convenience samples consisting of 75 subjects with eating disorders and 61 sex- and age-matched healthy controls. Study participants were female and the mean age was 22.9 (4.9 [SD]) years. Epoxide hydrolase 2 (EPHX2) genetic variations were significantly associated with AN risk, and epoxide hydrolase (sEH) activity was elevated in AN compared to controls. The polyunsaturated fatty acids (PUFAs) and eicosanoids data revealed that cytochrome P450 pathway was implicated in AN, and AN displayed a dysregulated postprandial metabolism of PUFAs and sEH-dependent eicosanoids. Implication and current initiatives: Collectively, our data suggest that dietary factors may contribute to the burden of EPHX2-associated AN susceptibility and affect disease outcome. We are implementing new investigations using a longitudinal study design in order to validate and develop an EPHX2 multi-omics biomarker system. We will test whether sEH-associated postprandial metabolism increases AN risk and affects treatment outcome through an ω-6 rich breakfast challenge. Participants will include 100 ill AN patients, 100 recovered AN patients, and 100 age- and race-matched healthy women. These data will allow us to investigate 1) how genetic and dietary factors independently and synergistically contribute to AN risk and progression, and 2) if clinical severity and treatment response in AN are affected by sEH activity and eicosanoid dysregulation. Results of our study will 1) identify clinically relevant biomarkers, 2) unravel mechanistic functions of sEH, and 3) delineate contributory roles of dietary PUFAs and cytochrome P450 pathway eicosanoids for the purpose of developing novel AN treatments and improving disease prognosis.

Soluble Epoxide Hydrolase Is Associated with Postprandial Anxiety Decrease in Healthy Adult Women

Integrating multi-omics biomarkers and postprandial metabolism to develop personalized treatment for anorexia nervosa

Estradiol-mediated protection against high-fat diet induced anxiety and obesity is associated with changes in the gut microbiota in female mice

Soluble Epoxide Hydrolase is Involved in the Development of Atherosclerosis and Arterial Neointima Formation by Regulating Smooth Muscle Cell Migration.

Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.

Ablation of Soluble Epoxide Hydrolase Expression Increases Beige Fat Over White Fat Through an Increase in Mitochondrial Integrity, Insulin Sensitivity and HO‐1‐PGC1α‐adiponectin in‐vitro and in‐vivo

Inhibition of Soluble Epoxide Hydrolase Alleviated Atherosclerosis by Reducing Monocyte Infiltration in Ldlr−/− Mice

Relationships between depression and anxiety symptoms and adipocyte-derived proteins in postmenopausal women

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases

Homocysteine Upregulates Soluble Epoxide Hydrolase in Vascular Endothelium in Vitro and in Vivo

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases.

Inhibition of Soluble Epoxide Hydrolase Ameliorates Hyperhomocysteinemia-Induced Hepatic Steatosis by Enhancing Β-Oxidation of Fatty Acid in Mice.

Cytochrome P450-soluble epoxide hydrolase derived linoleic acid oxylipins and cognitive performance in type 2 diabetes

Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides

Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide:diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity

Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice

Cytochrome P450-soluble epoxide hydrolase oxylipins, depression and cognition in type 2 diabetes

Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders

Abstract 542: the Effects of Soluble Epoxide Hydrolase Inhibition in Atherogenesis and Atherosclerotic Progression

Soluble Epoxide Hydrolase is Involved in Angiotensin II‐induced Atherosclerosis

Association Between Anxiety Level, Eating Behavior, and Nutritional Status in Adult Women